There has been a lapse in appropriated federal funds as of October 1, 2025. Grants.gov and Simpler.Grants.gov will still be available, but service may be delayed with reduced Federal support staff presence.
For those programs affected by the funding lapse, the Grants.gov and Simpler.Grants.gov systems will accept and store applications until such time as the responsible awarding agency has the authority and funding to return to normal business operations.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Agency: National Institutes of Health
Assistance Listings: 93.394 -- Cancer Detection and Diagnosis Research
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.
Eligibility
Eligible applicants
Government
- City or township governments
- State governments
- Public and Indian housing authorities
- Special district governments
- County governments
- Federally recognized Native American tribal governments
Education
- Private institutions of higher education
- Public and state institutions of higher education
- Independent school districts
Business
- For-profit organizations other than small businesses
- Small businesses
Nonprofit
- Other Native American tribal organizations
- Nonprofits non-higher education without 501(c)(3)
- Nonprofits non-higher education with 501(c)(3)
Miscellaneous
- Other
Additional information
Grantor contact information
Description
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Documents
File name | Description | Last updated |
---|---|---|
PAR-23-314-Full-Announcement.html | PAR-23-314 Full Announcement Text | Nov 1, 2023 05:59 PM UTC |
Link to additional information
https://grants.nih.gov/grants/guide/pa-files/PAR-23-314.html
Closing: October 15, 2025
Award
$--
Program Funding
--
Expected awards
$--
Award Minimum
$250,000
Award Maximum
Funding opportunity number:
PAR-23-314
Cost sharing or matching requirement:
Funding instrument type:
Cooperative agreement
Opportunity Category:
Discretionary
Opportunity Category Explanation:
Category of Funding Activity:
Education
Health
Category Explanation:
History
Version:
2
Posted date:
October 31, 2023
Archive date:
November 14, 2025